ArticleCellular oncology (Dordrecht, Netherlands)2026
A habitat radiomics model based on contrast-enhanced MRI for predicting early treatment response to hepatic arterial infusion chemotherapy in patients with unresectable hepatocellular carcinoma.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposeTo develop a contrast-enhanced Magnetic Resonance Imaging (CEMRI)-based habitat radiomics model for predicting early treatment response to hepatic artery infusion chemotherapy with fluorouracil, leucovorin, and oxaliplatin (HAIC-FOLFOX) in patients with unresectable hepatocellular carcinoma (HCC) and elucidate the underlying biological mechanisms.
methodsAmong 120 HCC patients who underwent HAIC treatment, habitat features were extracted by applying clustering algorithms to preoperative CEMRI to delineate intratumoral subregions with distinct enhancement characteristics. Least absolute shrinkage and selection operator (LASSO) and logistic regression were employed for feature selection to construct habitat, conventional radiomics, clinical, and combined models. Internal validation was performed using 1000 bootstrap resamples. In a separate cohort of 107 surgically resected HCC patients, the habitat model was applied for risk stratification, and correlations between habitat features and pathomorphological characteristics, as well as immunohistochemical (IHC) markers, were investigated.
resultsMRI images were categorized into three distinct habitats, and a predictive model was built from their proportional distribution. The habitat radiomics model achieved an area under the curve (AUC) of 0.868 (95% confidence interval (CI): 0.748–0.976), outperforming both conventional radiomics (AUC 0.849, 95% CI: 0.719–0.954) and clinical models (AUC 0.653, 95% CI: 0.497–0.802). The combined clinical-habitat model reached the highest AUC of 0.901 (95% CI: 0.795–0.989, P < 0.05). In the surgical cohort, low-risk habitat patients exhibited increased tumor necrosis/stromal components (elevated IntensityMin) and better differentiation (reduced CurvMean) (P < 0.05). Immunohistochemistry revealed higher microvessel density (CD34) and lower cancer stem cell marker expression (CK19, Glypican-3) in the low-risk group (P < 0.05).
conclusionThe CEMRI habitat radiomics model accurately predicts early HAIC treatment response, with risk stratification significantly correlated with pathomorphological and molecular characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.